Insulin-Like Growth Factor-1 Alleviates Expression of Aβ1–40 and α-, β-, and γ-Secretases in the Cortex and Hippocampus of APP/PS1 Double Transgenic Mice

[1]  S. Amini,et al.  Involvement of IRS‐1 Interaction With ADAM10 in the Regulation of Neurite Extension , 2014, Journal of cellular physiology.

[2]  H. Zhang,et al.  Alternations of central insulin‐like growth factor‐1 sensitivity in APP/PS1 transgenic mice and neuronal models , 2013, Journal of neuroscience research.

[3]  M. Laska,et al.  Olfactory and Visuospatial Learning and Memory Performance in Two Strains of Alzheimer's Disease Model Mice—A Longitudinal Study , 2011, PloS one.

[4]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[5]  M. Jensen,et al.  Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1ΔE9-deleted transgenic mice model of β-amyloidosis , 2010, Neurobiology of Aging.

[6]  S. Strittmatter,et al.  Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein , 2010, The Journal of Neuroscience.

[7]  C. Haass,et al.  Intramembrane Proteolysis by γ-Secretase* , 2008, Journal of Biological Chemistry.

[8]  G. Multhaup,et al.  IGF-1-induced Processing of the Amyloid Precursor Protein Family Is Mediated by Different Signaling Pathways* , 2007, Journal of Biological Chemistry.

[9]  N. Hooper,et al.  Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.

[10]  Brian J. Bacskai,et al.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease , 2006, Neurobiology of Disease.

[11]  J. Atack,et al.  A comparative assessment of γ-secretase activity in transgenic and non-transgenic rodent brain , 2006, Journal of Neuroscience Methods.

[12]  Ehud Cohen,et al.  Opposing Activities Protect Against Age-Onset Proteotoxicity , 2006, Science.

[13]  M. Ohno,et al.  Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1 , 2006, The European journal of neuroscience.

[14]  J. Atack,et al.  A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brain. , 2006, Journal of neuroscience methods.

[15]  R. Siman,et al.  Gamma-secretase subunit composition and distribution in the presenilin wild-type and mutant mouse brain , 2004, Neuroscience.

[16]  K. Yoo,et al.  Expression and changes of endogenous insulin-like growth factor-1 in neurons and glia in the gerbil hippocampus and dentate gyrus after ischemic insult , 2004, Neurochemistry International.

[17]  P. Wong,et al.  Binding Sites of γ-Secretase Inhibitors in Rodent Brain: Distribution, Postnatal Development, and Effect of Deafferentation , 2004, The Journal of Neuroscience.

[18]  C. Haass.  Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation , 2004 .

[19]  C. Haass.  Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. , 2004, The EMBO journal.

[20]  Richard Mayeux,et al.  Epidemiology of neurodegeneration. , 2003, Annual review of neuroscience.

[21]  S. Younkin,et al.  Genetic background regulates β-amyloid precursor protein processing and β-amyloid deposition in the mouse , 2003 .

[22]  T. Reisine,et al.  Cysteine proteases are the major β‐secretase in the regulated secretory pathway that provides most of the β‐amyloid in Alzheimer's disease: Role of BACE 1 in the constitutive secretory pathway , 2003, Journal of neuroscience research.

[23]  B. Lamb,et al.  Alterations in β-amyloid production and deposition in brain regions of two transgenic models , 2003, Neurobiology of Aging.

[24]  S. Younkin,et al.  Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. , 2003, Human molecular genetics.

[25]  T. Gómez-Isla,et al.  Serum insulin-like growth factor I regulates brain amyloid-β levels , 2002, Nature Medicine.

[26]  D. Selkoe.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. , 2002, The Journal of clinical investigation.

[27]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[28]  R. Doms,et al.  Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. , 2002, Biochemistry.

[29]  D. Selkoe.  Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.

[30]  P. Greengard,et al.  Stimulation of β-Amyloid Precursor Protein Trafficking by Insulin Reduces Intraneuronal β-Amyloid and Requires Mitogen-Activated Protein Kinase Signaling , 2001, The Journal of Neuroscience.

[31]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[32]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[33]  Clive R. Taylor,et al.  Sensitivity and detection efficiency of a novel two-step detection system (PowerVision) for immunohistochemistry , 1999 .

[34]  W. Hacke,et al.  Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury. , 1997, Stroke.

[35]  D. Le Roith,et al.  Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. , 1997 .

[36]  M. Carson,et al.  Insulin-like growth factor I increases brain growth and central nervous system myelination in tTransgenic mice , 1993, Neuron.

[37]  M. Carson,et al.  Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. , 1993, Neuron.

[38]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[39]  D. Teplow,et al.  Amyloid beta-peptide is produced by cultured cells during normal metabolism. , 1992, Nature.